Methotrexate Teva (Methotrexate)

Methotrexate inhibits dihydrofolate reductase, blocking the formation of tetrahydrofolate needed for purine and pyrimidine synthesis. This limits DNA, RNA and protein production in rapidly dividing cells, producing antineoplastic effects. At lower doses it increases extracellular adenosine, which suppresses inflammatory pathways in immune cells.

The dose of Methotrexate Teva is individualized by the prescribing clinician based on the specific indication, disease severity, patient weight, renal and hepatic function, and treatment response. No universal dosing regimen is provided; the prescriber sets the appropriate dose and schedule for each patient.

Methotrexate is classified as contraindicated in pregnancy because it can cause fetal malformations and miscarriage. Women of child‑bearing potential must use effective contraception during treatment and for a defined period after discontinuation. Limited data exist for breastfeeding, and the drug is generally avoided due to potential infant exposure.

To request Methotrexate Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Methotrexate is a small‑molecule antimetabolite that directly interferes with DNA synthesis, whereas many newer biologics target specific cytokines or cell‑surface receptors. Methotrexate is often less expensive and can be combined with biologics for synergistic effect, but it may have a broader toxicity profile, requiring regular laboratory monitoring.

Methotrexate Teva should be stored in a refrigerated environment between 2 °C and 8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If a temporary temperature excursion occurs, consult the product label before use.

Methotrexate Teva is supplied as an injectable solution for intra‑arterial or intravenous administration. The route, infusion rate, and frequency are determined by the treating physician based on the indication and patient factors. Administration is performed by qualified healthcare professionals in a clinical setting.

Serious risks include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to pancytopenia, renal failure, and life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be educated to report persistent cough, unexplained bruising, jaundice, severe abdominal pain, or rash promptly.

Methotrexate Teva is contraindicated in patients with known hypersensitivity to methotrexate, active severe infections, significant liver disease, uncontrolled renal impairment, and in pregnant or breastfeeding women. Caution is also advised for individuals with pre‑existing pulmonary disease or those receiving other myelosuppressive agents.